[Qiltrack AI] INVO Fertility Inc (IVF) 3-Minute Overview

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] INVO Fertility Inc (IVF) 3-Minute Overview > **💡 One-Sentence Summary** > > INVO Fertility is a tiny, highly speculative U.S. fertility-treatment play with fast-growing sales but massive losses, a stressed balance sheet, and a stock price that can move hundreds of percent in a day. > **📍 Basic Profile** > > Market Cap **$1.9 million** · Health Care · NASDAQ NMS - GLOBAL MARKET · Price **$3.80** (USD) > **⚡ 3 Things You Should Know** > > 1. 📈 **Wild volatility, penny-stock territory:** The stock just jumped about **+368% in a single session** (from $0.81 to $3.80), on a market cap under $2 million—this trades more like a lottery ticket than a stable investment. > > 2. 🔴 **Structurally unprofitable so far:** Despite an okay **gross margin (~39%)**, the company is burning cash at the bottom line with a **net margin around -417%** and **ROE about -322%**, which basically says the current business model is very far from break-even. > > 3. ⚠️ **Liquidity stress + “cheap for a reason” valuation:** On paper it looks ultra-cheap (**P/S ~0.28x, P/B ~0.11x**), but the **current ratio of 0.12 and quick ratio of 0.05** signal serious short-term funding pressure—survival likely depends on raising new capital or a major turnaround. --- > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-------------------|------------------------|---------| > | Profitability | Weak👎 | Net margin about **-417%**, ROE about **-322%** – deep losses despite decent gross margin | > | Growth Rate | Fast🚀 | 5-year revenue growth ~**35%** (3-year ~16%) but not translating into profits | > | Financial Health | Tight🧡 | **Current ratio 0.12**, quick ratio 0.05 – very tight liquidity despite only moderate leverage | > | Valuation | Cheap (with big asterisk) | **P/S ~0.28x, P/B ~0.11x**, but no PE due to losses – pricing reflects distress, not a healthy bargain | --- ## 📋 Layer 2: 2-Minute Deep Dive ### 📊 How Does This Company Make Money? **Business Model in One Sentence:** INVO Fertility operates in the fertility/IVF space, earning revenue from fertility treatment services and related healthcare offerings, typically on a per-treatment or service-fee basis. **Revenue Breakdown:** | Business | Share | Trend | Comment | |-------------------------------------|-----------------|-------|---------| | Fertility treatment services | [Data unavailable] | [Data unavailable] | Likely core revenue driver, but exact share not given in the data | | Other related products/services | [Data unavailable] | [Data unavailable] | Could include ancillary fertility-related offerings; details not provided | **Profitability Metrics (TTM):** | Metric | Value | Ranking | Interpretation | |--------------|------------:|----------------|----------------| | Gross Margin | **39.17%** | Average | The basic service economics aren’t terrible; there is room to make money at the gross level. | | Net Margin | **-417.01%**| Below Average | For every $1 of revenue, the company is losing over $4 at the bottom line – overhead and other costs are far too high relative to sales. | | ROE | **-321.75%**| Below Average | Shareholder equity is being heavily eroded; this is what you see when a very small equity base sits under very large losses. | --- ### 📈 How's the Growth? **Growth Assessment:** **High revenue growth, but low quality because it comes with massive, worsening losses.** | Metric | Latest | vs Last Year | Trend | |-----------------|------------:|---------------------|-------| | Revenue Growth | 3Y: **16.23%**; 5Y: **34.57%** | [Data unavailable] | Multi-year growth has been strong, but we lack year-by-year detail | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Quality:** From the data we have, **top-line growth looks real**, but it’s not being matched by any improvement in profitability. Big negative EPS surprises (see below) suggest that **costs, write-offs, or one-off items are blowing up the bottom line**, which is a red flag for the quality and sustainability of the growth story. --- ### 💰 Financial Health Check **One Sentence:** Financially, this looks like a person with a modest mortgage but almost no cash in the bank, bills due tomorrow, and income that doesn’t cover expenses. | Metric | Value | Safe Zone | Assessment | |-------------|----------------------------------|----------------|------------| | Debt Ratio | Proxy: Debt-to-equity **0.37x** | <0.60x (D/E) | ✅Safe on leverage – not overburdened with debt relative to equity | | Current Ratio | **0.123** | >1.5 healthy | 🚨Dangerous – very low; suggests difficulty covering short-term liabilities with current assets | | Current Quick Ratio | **0.0511** | >1.0 healthy | 🚨Dangerous – almost no liquid assets compared to short-term obligations | | Interest Coverage | **-7.71** | >3 comfortable | 🚨Dangerous – operating earnings are negative, so interest is being “covered” only through losses/other funding | | Cash Flow | [Data unavailable] | >0 | [Data unavailable] – but losses + low liquidity imply pressure | **Takeaway:** The **main risk is liquidity, not leverage**. Debt levels aren’t huge, but short-term solvency looks very tight. That often leads to **equity dilution, distressed financings, or restructuring** in microcaps like this. --- ### 🏷️ Is It Expensive Now? **Price Position (52-week range):** - 52-Week Low: **$0.71** - 52-Week High: **$148.32** - Current: **$3.80** → **Very close to the low** (roughly at the **2%** level of its 52-week range) So despite a huge one-day spike, the stock is still sitting near the very bottom of a massively deflated 52-week range (likely influenced by reverse splits and prior spikes). | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|-----------|-----------|-------------| | Criteria | 0–33% | 33–66% | 66–100% | | **Current** | ● (~2%) | | | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |-----------------|----------------------------|---------------------------|------------| | vs Own History | PE: **N/A (loss-making)** | 5-year avg PE: [Data unavailable] | Cannot compare on PE due to persistent losses | | vs Own History | P/S: **~0.28x** | 5-year avg P/S: [Data unavailable] | Very low on absolute basis for a healthcare service company | | vs Own History | P/B: **~0.11x** | 5-year avg P/B: [Data unavailable] | Deep “discount to book”, often a distress signal | | vs Peers | PE: N/A vs industry | [Data unavailable] | Not meaningful vs profitable peers | | vs Peers | P/S, P/B vs industry | [Data unavailable] | Likely cheaper than typical healthcare peers, but with far higher risk | **What the Current Valuation is Betting On:** Basically, the current valuation says: - **The market has very low confidence in survival and/or future profitability.** - It’s **pricing in a high risk of dilution, restructuring, or failure**, which is why multiples are so low. - For a bull case to work, you’d be betting on **a successful turnaround, access to fresh capital, and scaling the business to a point where the high gross margins start to matter**. This is more of a **turnaround/speculation** than a typical value play. --- ### 📰 Any Recent News? The provided dataset doesn’t include any specific recent news items. | Date | Event | Impact | |------|-------|--------| | [Data unavailable] | No major news provided in the dataset | [Data unavailable] | Given the **+368% price move in one day**, there is likely some catalyst (corporate action, financing, clinical/operational update, reverse split, or low-float squeeze), but it’s **not included in the structured data** you provided. --- ## 📊 Layer 3: 3-Minute Complete Analysis ### I. Detailed Financial Data **Profitability Trends:** (We only have TTM snapshot data, not full multi-year history.) | Metric | This Year (TTM) | Last Year | Year Before | 3-Year Trend | |-------------|-----------------:|----------:|------------:|--------------| | Gross Margin | **39.17%** | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | **-417.01%** | [Data unavailable] | [Data unavailable] | [Data unavailable] | | ROE | **-321.75%** | [Data unavailable] | [Data unavailable] | [Data unavailable] | Even without the trend, the current snapshot alone is telling: **very deep losses** relative to sales and equity. **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |---------------|----------:|----------:|------------:|--------------| | Revenue Growth| [Data unavailable] | [Data unavailable] | [Data unavailable] | Multi-year avg: **16.23% (3Y)**, **34.57% (5Y)** | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | EPS Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | 3Y & 5Y EPS growth: **[Data unavailable]** | So we know **revenue has grown**, but without clear yearly EPS trends—other than very negative recent EPS—it looks like **losses have not been brought under control**. --- ### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter End | EPS Expected | EPS Actual | Surprise | Comment | |----------------|-------------:|-----------:|----------:|---------| | 2025-09-30 | **-0.0404** | **-0.77** | **-0.73** | About **-1806% miss** – far worse than the already negative expectation | | 2024-12-31 | **-84.84** | **-620.88**| **-536.04** | Around **-632% miss** – enormous negative surprise; likely includes special items or accounting impacts | | 2023-09-30 | [No estimate] | **-0.70** | N/A | EPS negative; no consensus to compare | | 2023-06-30 | [No estimate] | **-3.06** | N/A | EPS negative; no consensus to compare | **Earnings Trend Interpretation:** - Where estimates existed, the company **missed by a huge margin twice in a row**, which tends to: - Hurt **credibility of management guidance**. - Make future estimates more cautious and investors more skeptical. - Those giant negative EPS numbers (especially -620.88) often involve **reverse splits, one-time charges, or recapitalization events**, but the key message is: **earnings volatility is extreme and not in a good way.** --- ### III. What the Market Thinks **Analyst Ratings (most recent period: 2026-01-01):** | Rating | Count | Percentage | |-----------------|------:|-----------:| | Strong Buy/Buy | 4 | **80%** | | Hold | 1 | **20%** | | Sell/Strong Sell| 0 | 0% | So among the limited coverage it has, **most analysts are positive or speculative-bullish**, which can happen with small caps where analysts are betting on a turnaround or niche growth story. **Target Price:** Target price range: **[Data unavailable]** (not included in the dataset) vs Current Price: **[Data unavailable]** upside/downside – so we can’t quantify the implied return. **Insider Activity (last disclosed transactions):** - Recent activity shows **small net selling** by insider **Matthew K Szot** (total change -7 shares in December 2025). - The absolute number of shares is **tiny**, so: - Economically, it’s likely **not very meaningful**. - It doesn’t look like a major confidence signal either way. > In general, **large, consistent insider buying** can be a strong positive signal; small, one-off selling—especially in microcaps—can be driven by many personal factors and is less informative. --- ### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Liquidity / Going-Concern Risk:** - Current ratio **0.12** and quick ratio **0.05** mean the company has **very little liquid assets relative to short-term liabilities**. - If it cannot refinance, roll over liabilities, or raise fresh equity/convertible funding, it could face **severe financial stress or restructuring**. 2. **Continued Heavy Losses & Dilution Risk:** - Net margin **-417%** and ROE **-322%** show that losses are extremely large relative to the size of the business. - In practice, such companies often survive by **issuing new shares or dilutive securities**, which can **crush existing shareholders’ ownership percentage and per-share value**. 3. **Extreme Volatility & Microcap Risk:** - Market cap is only about **$1.9 million**, beta is **~2.67**, and the stock moved **+368% in one day**. - This kind of profile is prone to **sharp spikes and crashes, low liquidity, and potential “story stock” or trading-driven moves** rather than fundamentals—making it unsuitable for investors who can’t tolerate very high risk and drawdowns. --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** INVO Fertility is a tiny, speculative fertility/IVF healthcare company with growing revenues but extremely weak profitability and a very stressed near-term liquidity position. > **Key strength:** It operates in a structurally growing niche (fertility services) and has shown solid multi-year revenue growth with decent gross margins, which at least gives some foundation for a turnaround story. > **Key risk:** The combination of deep losses, dangerous liquidity ratios, and microcap volatility means the path forward almost certainly involves **more capital raises and high execution risk**, so this behaves more like a high-risk speculation than a conventional long-term investment. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a real competitive moat or just a niche story? → Try **【Buffett Mode】** for deeper business-model and moat analysis. > • Worried about hidden landmines (dilution, covenants, going-concern warnings)? → Try **【Muddy Mode】** for risk and balance-sheet deep dive. > • Thinking of it as a high-risk growth bet and want to see if the math can work? → Try **【Musk Mode】** for scenario modeling and growth valuation.